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The direct effect of cyclosporin A on epidermal cells was 
exa mined by using a pig skin explant culture sys tem. A 
dose-response study using cyclosporin concentration from 
one- tenth the expected serum level to 100 times the ex-
pected serum level was done, and epidermal outgrowth 
and the number of mitotic fi gures were measured. Cy-
closporin inhibited epidermal cell outgrowth at con centra-
Recently, the widely used immunosuppressive agent cyclospo rin A [1-3] has been reported to be etTective in psoriasis [4-6] and ichth yosis [7] when it was used systemi ca lly . Although both psoriasis and ichthyos is are disorders of keratinization, there is a considerable 
diffe rence between these 2 diseases; psorias is is a disease thought 
to be related to T -lymphocy te function [8-11] , but ichthyosis is 
th ought to be only an epidermal disease . We present the results 
of the direct effects of cyclosporin on pig sk in explant cultures. 
The lack of any direct effect wilJ have to be ex plained in discus-
sions of the beneficial effe ct of cyclosporin on these skin di seases . 
MATERIALS AND METHODS 
Sk in sl.i ces were taken from the backs of small domestic pigs with 
a Castroviejo keratome set at a 0.2-mm depth . Multiple 2 x 2 
mm sk in pieces were prepared by cuttin g with a sharp scalpel 
an d were placed dermis-side-down on glass coverslips in 3.5-cm 
Falcon Petri dishes and covered with 2 ml of culture medium. 
T he growth n1.ed iulll consisted of RPM I 1640 with 10% fetal calf 
serum (FCS) plus antibiotics (penicillin 200 U/ ml , streptomycin 
200 ILg/ml , amphotericin B 0. 5 ILg/ ml , and mycostatin 100 U / 
ml) . C ultures were incubated in a humidified incubator in an 
atmosphere of95% air/5% ca rbon dioxide. After 96 h of gro wth , 
we measured the outgrowth of each explant and the medium w as 
changed to new medium with 5% FCS plus antibiotics and con-
taining different concentrations of cyclosporin. After an addi-
tional 72 h of growth, each outgrowth was measured again, and 
1-3 ILg/ml colchi cine was added for 4 h. After fixation and stain-
ing, mitoti c figures were counted using essentially the same meth-
ods described in [12,13]. 
Fetal calf serum , RPMI 1640 media, and antibioti cs were ob-
tained from GIBCO (Grand Island , N ew York) , colchicine was 
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tions of 60 and 100 times the expected serum level, but it 
did not inhibit epidermal cell outgrowth at the serum level 
or even at 30 times the serum level. Cyclosporin did not 
inhibit mitotic fi gures signifi cantly . These results suggest 
that cyclosporin does not inhibit epidermal cells directly· 
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obtained from Eli Lill y and Compan y (Indianapolis, Indiana), and 
cyclosporin (intravenous agent) was obtained from Sandoz In C. 
(East H anover, N ew Jersey). All other chemicals were of ana-
lytical reagent g rade. 
RESULTS 
We ca rried out a dose-response study usin g concentrations of 
cyclosporin from one-tenth the expected serum level to 100 times 
the serum level. T able I shows the res ults of 7 different experi-
ments . Serum level was taken as 200 ng/ml acco rding to previouS 
reports [14,15] . There was no inhibitory effe ct on the outgrowth 
of explants lip to a concentration of 30 times the serum level 
compared witb the control, but there were inhibitory effects af 
concentrations of 60 and 100 times the serum level. The meaIl 
percentage of ou tgro wth at 60 times is 43 ± 6.98(SEM) %, and 
the mean at 100 times is - 12 ± 8.37(SEM) % com pared with 
control. 
Figure 1 shows the typi ca l explant samples of the no rmal con-
trol (A), at the serum level of cyclosporin (B), and at 100 times 
the serum level of cyclosporin (C) after 72 h of incubation. The 
length of outgrowth is less at 100 times the serum level , and the 
number of layers from the edges of the original skin was greater 
than normal control or serum level. When we changed the me-
dium from 100 times the serum level to a new control mediu I11 
again after 72 h of incubation, explants started to grow again and 
the thickness of the layers became normal. This suggests th at the 
explants were not killed by 100 times tbe serum level of cyclo-
sporin; they were only inhibited from growing during direCf 
exposure to the dru g. 
After meas urin g the outgrowth, the medium w as changed to 
a medium containing 1-3 ILg/ ml colchicine and the tissue was 
incubated for 4 h at 37"C. After staining with 1 % toluidine blue 
the mitotic figures were counted (Table II). In 2 of3 experimenfs 
with 3 ILg/ml of colchicine there w as no inhibition of mitoSIS 
(Ex. 6 and Ex. 7). In the single ex periment with 1 ILg/ml col-
chicine (Ex . 4) , both 60 and 100 times the serum concentratioIl 
showed sli ght inhibition. Mitotic figures after colchicine inCU-
bation were more easily seen with 3 ILg/ml of colchicine. There 
is, therefore , either no effect at all on mitoti c activity or a slight 
effect at high concentrations that is less than the effect on the 
outgrowth size. 
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Table I. Effect of Cyclospo rin o n E piderlll al O utgrowth 
--------------------------------------------------------------------------------------------------------------------
Ex . I Ex. 2 Ex. 3 Ex. 4 Ex. 5 Ex . 6 Ex. 7 
---------------------------------------------------------------------------------------------------------------------Control )( 10 100 (9) 124 (7) 
107 (S) 
103 (9) 





11 4 (13) 129 (10) 153 (14) 
96 (17) 153 (10) 11 5 (14) 87 (9) 100 (15) 
S8 (13) 143 (14) 121 (17) 115 (7) 92 (13) 143 (13) 
10 1 (16) 97 ( IS) 105 (7) 102 (9) 107 (16) 
X 100 
59 (12) 44 (15) 23 (7) 57 (10) 32 (16) 
-4 1 (S) 4 (12) - 1 (12) - 27 (16) -21 (S) 12 (17) 
--------------------------------------------------------------------------------------------------------------------
v tft cr ~a 72-h incubatio n in each medium with or w ith o ut cyclospo rin . the leng th of the explant o utgrowth was measured and ex pressed as a percentage of each contro l 
E'u c. 1 he numbe r of sa m p,,"s is in pa rentheses. T he m icro ns of outg rowth of each co ntro l were as fo llows: Ex. I = 442.2 . Ex. 2 = 38 1.6. Ex . 3 = 30 1.6. Ex. 4 = 222.0. 
x. 5 = 47(,.0. Ex. 6 = 292.0. Ex. 7 = 246.0. Serum le vel of cyc1osporin was taken as 200 ng/ ml. 
DI SC USSI O N 
(Yclospo rin A is an imlllunos uppressive agent widel y used in 
~Ull1all o rgan transpl antati o n [1-3]. The m echanism o f acti o n of 
t liS dru g is now under in vesti ga tio n b y m any g ro ups. Merker 
and H andschum acher 11 6] o bse rved , by usin g the murin e th y-
;lloma cell lin e, th at m ost o f the dru g concentrated by cells is 
° fated III th e cytosol, and Kro nk e et al [1 71 repo rted that it 
In llbits T-cell g ro wth fac to r gene expressio n at the level o f mRNA 
trallSc' . . 
. nptl o n . Al so cyclospo rIn has been used fo r trea tm ent o f 
aUtOimmune diseases [2, 181. In de rm ato logy, o ral use o f cyclo-
sPOnn fo r g raft- versus-host disease [1 9] and the treatm ent of cu-
taneous T-cell lympho m a [201 we re repo rted. 
ti v~o reover , cyclospo rin w as r eported recentl y to be ve ry effe c-
. 111 trea tlll g pSO riaSIS w hen It w as used syste mi ca ll y [4-6 ], and 
It Was also repo rted to ca use impro ve m ent in ichth yos is [7] . Sin ce 
Pso n aSls and ichth yosis arc bo th diseases with di so rders o f ker-
~tlndl za tion , we exa min ed the effect of cyclos po rin direc tl y o n th e 
Pi erm al cells. 
Altho ugh cyclospo rin inhibited epiderm al cell o utg rowth at 
con centratio ns 60 and 100 tim es the serum level (T abl e I) o r 
~I thses (T able II) in our study , it could no t inhibit cell o utg ro wth 
it tl e serum level o r even at 30 tim es th e serum level. Cyclospo rin 
eSf~ lerefo re unlikely to ac t in psorias is and in ich thyos is b y a direc t 
ect 0 11 ep iderm al cells. 
b Alth o ug h the primary defect in psorias is is usuall y th o u ght to 
r
C 
enhanced epiderm al cell proliferatio n, pso rias is has also been 
aepOrted to have a de fective fun ctio n o f T lymphocy tes [8] and 
an Increased helper-suppressor T-cell rati o [101 . Discussio ns o f 
~ POSSible immune bas is were repo rted [9, 11] . So it m ay be that 
i~~i~al~ ex plain the e ffect o f cyclospo rin o n pso rias is thro ug h 
ItIOn o f T -l ymphocy te actio n . 
A 
Table II. Effect of Cycl ospo rin o n Mi to ti c Fig ures 
Ex.4 Ex. 6 Ex. 7 
Control 4.1 (14) 3.0 (8) 2.S (17) 
x-(u 3.2 (10) 3. 4 (14) 
Serum 3.0 (14) 2.6 (9) 3. 1 (IS) 
x lO 2.9 (17) 2.9 (13) 3.2 (13) 
x 30 2.5 (IS) 3.2 (9) 3.4 (16) 
x 60 1. 6 (15) 3.2 (10) 4.2 (16) 
x 100 1.7 (16) 2.8 (S) 3.4 (17) 
After a 72-h incubat io n in each m ediul11 w ith or witho ut cyclosporin . the mediu m 
WJS changed to med ium contai ning I (Ex. 4) o r 3 (Ex. (, and Ex . 7) JLg/ ml colchi ci ne 
ond the tissue was incubated fo r 4 h ot 37'C. Afte r sto in ing w ith I % to luid ine blue 
the llu ll1bcrs of mitotic fig ures were cO lill ted . T he nu mbe r of samples is ill pan.'n-
theses. 
T ho ug h severe toxicities o f cyclospo rin have been repo rted 
[1 5,21-24], m o re to pi ca l derm ato logic trial s m ay be worth w hi le, 
as has been po inted o ut b y Aldrid ge et al [25]. H owever, the 
am o unt of th e dru g reachin g the syste mi c ci rculatio n b y to pi ca l 
applica tio n m ay beco m e equal to ora l ad minist rati o n. 
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